



Published in final edited form as:

*Purinergic Signal*. 2005 September ; 1(3): 241–247.

## Signaling of the Human P2Y<sub>1</sub> Receptor Measured by a Yeast Growth Assay with Comparisons to Assays of Phospholipase C and Calcium Mobilization in 1321N1 Human Astrocytoma Cells

Ronald T. Niebauer<sup>a,b</sup>, Zhan-Guo Gao<sup>a</sup>, Bo Li<sup>c</sup>, Jürgen Wess<sup>c</sup>, and Kenneth A. Jacobson<sup>a,\*</sup>

<sup>a</sup>Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0810, USA

<sup>c</sup>Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0810, USA

<sup>b</sup>Department of Chemical Engineering, University of Delaware, Newark, DE 19716, USA

### Abstract

The human P2Y<sub>1</sub> receptor was expressed in the yeast *Saccharomyces cerevisiae* strain MPY578q5, which is engineered to couple to mammalian G protein-coupled receptors (GPCRs) and requires agonist-induced activation for growth. A range of known P2Y<sub>1</sub> receptor agonists were examined with the yeast growth assay system, and the results were validated by comparing with potencies in the transfected 1321N1 astrocytoma cell line, in which calcium mobilization was measured with a FLIPR (fluorescence-imaging plate reader). The data were also compared with those from phospholipase C activation and radioligand binding with the use of a newly available radioligand [<sup>3</sup>H]MRS2279 (2-chloro- N<sup>6</sup>-methyl-(N)-methanocarpa-2'-deoxyadenosine-3',5'-bisphosphate). In the yeast growth assay, the rank order of potency of 2-MeSADP (2-methylthioadenosine 5'-diphosphate), ADP (adenosine 5'-diphosphate), and ATP (adenosine 5'-triphosphate) is the same as those in other assay systems, i.e., 2-MeSADP>ADP>ATP. The P2Y<sub>1</sub>-selective antagonist MRS2179 (N<sup>6</sup>-methyl-2-deoxyadenosine-3',5'-bisphosphate) was shown to act as an antagonist with similar potency in all systems. The results suggest that the yeast expression system is suitable for screening P2Y<sub>1</sub> receptor ligands, both agonists and antagonists. The yeast system should be useful for random mutagenesis of GPCRs to identify mutants with certain properties, such as selective potency enhancement for small synthetic molecules and constitutive activity.

### Keywords

Calcium mobilization assay; GPCR; nucleotides; nucleotide receptor; P2Y<sub>1</sub> agonists; P2Y<sub>1</sub> antagonist; P2Y<sub>1</sub> receptor; signal transduction; yeast growth assay

### Introduction

Extracellular purines are important signaling molecules responsible for biological effects mediated by cell surface receptors [1-3]. The family of purine receptors includes adenosine (P1 receptors) and P2 receptors. The P2 class, which primarily recognizes ATP (adenosine 5'-triphosphate) and ADP (adenosine 5'-diphosphate), has been subdivided into subfamilies of P2X ligand-gated ion channels and P2Y seven-transmembrane-spanning G protein-coupled receptors (GPCRs).

\*Corresponding author. Tel.: +1-301-496-9024; fax: +1-301-480-8422. E-mail address: kajacobs@helix.nih.gov (K.A. Jacobson)

The P2Y<sub>1</sub> receptor couples preferentially to G<sub>q</sub>, which activates phospholipase C<sub>β</sub> (PLC), leading to formation of inositol trisphosphate (IP<sub>3</sub>) and mobilization of intracellular Ca<sup>2+</sup>. Various assays are available to measure the downstream signaling, with measurement of PLC being a common, classical technique [4]. Previous reports showed that assay results may vary significantly, depending on the signaling variable measured [5,6]. In this investigation we set out to establish the yeast assay system and to compare measurement at this level of the signaling cascade, which is dependent on activation of the G protein, with other, subsequent levels, i.e., PLC and Ca<sup>2+</sup>. The compounds tested in this set of experiments included ADP, ATP, 2-MeSADP (2-methylthioadenosine 5'-diphosphate), ADP-β-S (adenosine 5'-O-(2-thio-diphosphate), HT-AMP (2-hexylthioadenosine 5'-monophosphate), PAPET-ATP (2-[4-amino (2-phenylethyl)thio]-ATP), and 3AM-ATP (3'-amino-3'-deoxy-ATP) [7,8,9]. The bisphosphate antagonist MRS2179 (*N*<sup>6</sup>-methyl-2'-deoxyadenosine-3',5'-bisphosphate) [10], which is highly selective for P2Y<sub>1</sub> receptors, was also tested.

The yeast *Saccharomyces cerevisiae* was used to measure functional effects at the G protein level. This yeast strain has a native signaling system to regulate mating [11]. Specifically, a GPCR (Ste2p) is activated by mating pheromones, which bind to Ste2p, triggering a cascade of events ultimately leading to up-regulation of mating-specific genes and down-regulation of other pathways. This particular system has been engineered to couple to mammalian GPCRs [12-16]. Several genetic modifications were required for this purpose, including modification of the G protein α subunit, deletion of certain genes, and insertion of reporter genes. Yeast assays for GPCRs have grown in popularity, primarily because of the well-known genetics of yeast, making manipulations straightforward, and the ability to directly analyze a particular receptor in the absence of other receptor subtypes. The speed of yeast growth allows broad screening and use of random mutagenesis of GPCRs to identify mutants with certain properties, such as selective potency enhancement for small synthetic molecules and constitutive activity [16,17].

The results from the yeast system were compared to pharmacological parameters reflecting later steps along the signaling cascade, measured for the same compounds: activation of PLC and calcium mobilization. PLC results were obtained from the 1321N1 astrocytoma cell line expressing P2Y<sub>1</sub> receptors as reported previously [18,19], and calcium levels were monitored in the same cell line. We set out to explore the yeast system for P2Y receptors, not only for conventional compound screening at the native receptors, but also to develop genetically engineered receptors. Because it is possible to introduce random mutagenesis and to select for responsive clones [16,17] by cell growth, yeast promises to be a unique screening tool. One possible use is identification of mutant receptors (e.g., neoreceptors) with enhanced pharmacological properties [20].

## Materials and Methods

### Materials

Yeast media components were purchased from Qbiogene, Inc (Carlsbad, CA, USA). The calcium assay kit was from Molecular Devices (Sunnyvale, CA, USA). The compounds 3-amino-1,2,4-triazole (3-AT), probenecid, ADP, ATP, 3AM-ATP, 2-MeSADP, ADP-β-S, and MRS2179 were from Sigma (St. Louis, MO, USA); HT-AMP, PAPET-ATP, and [<sup>3</sup>H] MRS2279 were synthesized as previously reported [21-23].

### Yeast strain

The yeast *Saccharomyces cerevisiae* strain MPY578q5 (*MATa GPA1 far1::LYS2 fus1::FUS1-HIS3 sst2::SST2-G418<sup>R</sup> ste2::LEU2 fus2::FUS2-CAN1 ura3 lys2 ade2 his3 leu2 trp1 can1*) was used for expression experiments as previously described [24,17]. This strain contains a

mutant version of the *GPA1* gene that codes for a  $G\alpha$  subunit in which the last five amino acids are derived from the mammalian  $\alpha_q$  (EYNLV). In addition, the deletion of the *FAR1* gene allows yeast to grow despite activation of the pheromone pathway that normally leads to cell-cycle arrest. The *SST2* gene was disrupted to prevent attenuation of G protein signaling mediated by the GTPase-activating protein activity of Sst2p. The *STE2* gene coding for the yeast  $\alpha$  factor receptor was deleted to prevent competition for G proteins. The *FUS1-HIS3* reporter makes the production of the His3 protein dependent on receptor-mediated activation of the yeast pheromone pathway.

### Yeast expression plasmid

Expression plasmids used were based on p416GPD [24], which is a single-copy plasmid containing the *CEN/ARS* element, the *URA3* gene as a selection marker in yeast, the *Amp* gene for selection in *Escherichia coli*, and the yeast GAPDH (glyceraldehyde-3-phosphate dehydrogenase) promoter. In particular, human P2Y<sub>1</sub> was subcloned from pCD-PS [25] into p416GPD to create p416-P2Y<sub>1</sub>, which was confirmed by DNA sequencing.

### Yeast transformation and growth

Yeast cells were grown at 30°C at 180 rpm in synthetic complete (SC) media [26] unless otherwise noted. Yeast transformations were performed with a lithium acetate technique [27]. Transformants were selected and maintained in SC media lacking uracil (SC-URA).

### Yeast liquid growth assay

Cells were grown overnight in 2 ml SC-URA. Cells were then washed once with PBS and used at a working concentration of ~50000 cells/ml (based on the conversion OD 0.1 ~  $3 \times 10^6$  cells/ml) in SC media lacking uracil and histidine (SC-URA-HIS) with 20 mM 3-AT. 3-AT is an inhibitor of imidazole glycerol-phosphate dehydrase, which decreases basal cell growth in histidine-deficient media because of leaky expression of *FUS1-HIS3*. A quantity of 180  $\mu$ l cells was added to each well of a flat-bottom 96-well plate. Then 20  $\mu$ l of either compound at the appropriate dilution or water (negative control) or histidine stock (positive control) was added to each well. For antagonist studies, 20  $\mu$ l of both agonist and antagonist was added to each well. Plates were incubated at room temperature for several days. Immediately before measurement, the contents of each well were pipette mixed, and the optical density at 630 nm was measured with a plate reader. Samples were run in triplicate and averaged.

### Calcium mobilization assay

Human 1321N1 astrocytoma cells stably expressing human P2Y<sub>1</sub> receptors were cultured in Dulbecco's modified Eagle's medium (JRH Biosciences, Inc., Lenexa, KS, USA) and F12 (1:1) supplemented with 10% fetal bovine serum, 100 units penicillin/ml, 100  $\mu$ g streptomycin/ml, 2  $\mu$ mol glutamine/ml, and 500  $\mu$ g geneticin/ml. For the assay, cells were grown overnight in 100  $\mu$ l media in 96-well flat-bottom plates at 37°C at 5% CO<sub>2</sub> or until they reached ~60–80% confluency. The calcium assay kit (Molecular Devices) was used as directed with no washing of cells and with probenecid added to the loading dye at a final concentration of 2.5 mM to increase dye retention. Cells were loaded with 50  $\mu$ l dye with probenecid in each well and incubated for 45 min at room temperature. The compound plate was prepared with dilutions of various compounds in Hanks Buffer. For antagonist studies, both agonist and antagonist were added to the sample plate. Samples were run in duplicate with a Molecular Devices Flexstation I at room temperature. Cell fluorescence (excitation = 485 nm; emission = 525 nm) was monitored following exposure to compound. Increases in intracellular calcium are reported as the maximum fluorescence value after exposure minus the basal fluorescence value before exposure.

## Binding assay

P2Y<sub>1</sub> receptor binding experiments were performed as previously described [23]. Briefly, membranes (40 µg protein) from astrocytoma cells stably expressing human P2Y<sub>1</sub> receptors were incubated with [<sup>3</sup>H]MRS2279 (8 nM) for 30 min at 4°C in a total assay volume of 200 µl. The radiolabeled-ligand concentration used in the assay approximated the K<sub>d</sub> value in binding to the receptor. Binding reactions were terminated by filtration through Whatman GF/B glass-fiber filters under reduced pressure with a MT-24 cell harvester (Brandel, Gaithersburg, MD), and radioactivity was determined with a liquid scintillation counter (Packard, Downers Grove, IL).

## Statistical analysis

Binding and functional parameters were estimated with GraphPad Prism software (GraphPad, San Diego, CA, USA). Antagonist potency was evaluated by Schild analysis [28]. The concentration ratio is equal to the EC<sub>50</sub> of the agonist in the presence of the antagonist divided by the EC<sub>50</sub> of the agonist alone. K<sub>B</sub> is the Schild constant of the antagonist. Data are expressed as mean ± standard error.

## Results

### Agonist effects on P2Y<sub>1</sub> receptors in the yeast system via growth assays

A yeast expression system was used for measurement of G protein activation via P2Y<sub>1</sub> receptors. To determine if the human P2Y<sub>1</sub> receptor could effectively couple to a G protein, the haploid yeast (*S. cerevisiae*) strain MPY578q5 was used [24,17]. The basic features of this strain include numerous modifications to the native yeast pheromone response pathway, including expression of a chimeric G<sub>q</sub> protein, such that it required productive receptor–G protein coupling for growth in histidine-deficient media. This yeast strain harbors a mutant version of the *GPA1* gene coding for a hybrid yeast/mammalian G protein subunit in which the last five amino acids of Gpa1p were replaced with the corresponding residues present in mammalian α<sub>q</sub>[24]. This strain was then transformed with the human P2Y<sub>1</sub> gene in a yeast expression plasmid. To determine conditions for effective coupling, liquid growth assays were performed. Care was taken to use 3-AT as shown previously to suppress basal growth [24, 16]. To validate the effectiveness of the system, we first tested two agonists, including the endogenous P2Y<sub>1</sub> receptor agonist ADP and the classical agonist 2-MeSADP. Basal growth was low in the absence of any exogenously added nucleotides and in the presence of UDP (data not shown), which was shown to be relatively inactive at the P2Y<sub>1</sub> receptor. The positive control (addition of histidine to the media to check cell viability) showed that the agonists examined were fully efficacious. These data showed that the chimeric G protein was effectively coupled to the human P2Y<sub>1</sub> receptor, which was important to establish because many chimeras do not effectively couple in yeast [29].

To compare present results with the available PLC data, 2-MeSADP, ADP, and ATP were studied. As shown in Figure 1, the rank order of these three compounds was similar to that of the published PLC data (Table 1).

To further test the yeast system, ADP-β-S, HT-AMP, and two amine-derivatized agonists, PAPET-ATP and 3AM-ATP, were included. The amine-derivatized agonists were demonstrated to be moderately potent in a PLC assay or have moderate affinity in binding [18,19]. Because of the charged amino group at the 3' position, 3AM-ATP has possible future applications in helping to determine interactions within the binding site at the molecular level (see Discussion). The resulting EC<sub>50</sub> values for all the compounds are shown in Table 1. In general, the compounds were equally potent in the yeast assay and in the PLC assay.

### Antagonist effects on P2Y<sub>1</sub> receptors in the yeast system via growth assays

To show that the results obtained were specific to P2Y<sub>1</sub> receptors in the yeast system, the P2Y<sub>1</sub>-selective antagonist MRS2179 was studied. The data obtained from the liquid growth assay are shown in Figure 2. In this experiment the agonist ADP was used as an activator of the P2Y<sub>1</sub> receptor, and MRS2179 antagonized the effects of ADP by causing a right shift in the curve.

### Agonist effects on P2Y<sub>1</sub> receptors in astrocytoma cells via calcium assays

We compared the agonist effects by using a different second messenger, the increase in intracellular calcium upon ligand exposure. These experiments were performed on astrocytoma cells expressing the human P2Y<sub>1</sub> receptor. Upon addition of a nucleotide ligand, the calcium mobilization was determined by the increase in fluorescence in response to a calcium-sensitive dye. In control experiments, the absence of added nucleotides or the addition of UDP or UTP did not induce any response. In addition, astrocytoma cells (not expressing P2Y<sub>1</sub> receptors) showed no response to either ATP or ADP (data not shown). The same set of compounds used in the yeast system was tested in the astrocytoma system (Table 1). As was seen with the yeast system and the PLC assays, the rank orders of 2-MeSADP, ADP, and ATP as agonists were consistent. The EC<sub>50</sub> values for all the compounds are shown in Table 1. In the calcium system, the EC<sub>50</sub> values were consistently lower than those in the PLC and binding assays and the yeast assay. The rank orders of several of the known compounds, 2-MeSADP, ADP, and ATP, were consistent across the systems. However, ADP-β-S, HT-AMP, and PAPET-ATP were more potent in the calcium measurement than in other assays.

### Antagonist effects on P2Y<sub>1</sub> receptors in the astrocytoma system

Intracellular calcium can be regulated by various stimuli; therefore, to show consistency and specificity for the P2Y<sub>1</sub> receptor, the antagonist MRS2179 (with ADP as an agonist) was tested with the astrocytoma system (Figure 3a). As shown in Figure 3b, Schild analysis provided a K<sub>B</sub> value of 164 nM, which was comparable to the value of K<sub>B</sub> = 177 nM for MRS2179 previously reported [30]. Because this is a selective antagonist, it can be used as a control to show that the previous calcium results were specific and not artifacts of another receptor or pathway.

Because HT-AMP was much more potent in the calcium assay than in the yeast assay, it was important to demonstrate that HT-AMP acts as an agonist specifically on P2Y<sub>1</sub> receptors to induce calcium mobilization. To confirm this, the antagonist effects of MRS2179 were tested with HT-AMP as the agonist (Figure 4a). Schild analysis gave a K<sub>B</sub> value of 70 nM, which was similar to that obtained with ADP as an agonist (Figure 4b).

### Competition of agonists for the [<sup>3</sup>H]MRS2279 binding to membranes from astrocytoma cells stably expressing human P2Y<sub>1</sub> receptors

Because a clear discrepancy between the data for some agonists in the yeast assay and in the calcium assay was observed, we further examined the binding affinity of these compounds for the human P2Y<sub>1</sub> receptor. HT-AMP, ADP-β-S, and PAPET-ATP were shown to be much less potent in the binding assay than in the calcium assay (Table 1). The antagonist radioligand was used in the binding assay to test the agonist potency, and the high-affinity and low-affinity binding sites of these agonists have been analyzed.

## Discussion

It was shown that the yeast system showed good signal-to-noise ratios and low basal growth, suggesting that it can be used in screening ligands for P2Y<sub>1</sub> receptors. The data from the yeast growth assays were generally consistent with those from the previous assays of inositol



phosphates accumulation. The rank order for 2-MeSADP, ADP, and ATP is consistent for the different techniques. All of the compounds tested, including ATP, produced a maximal or nearly maximal effect in the yeast growth assay. However, we cannot conclude that ATP itself is a nearly full agonist in this system, because cleavage of ATP to form the full agonist ADP could not be ruled out. In all the systems, the antagonist MRS2179 was able to right-shift the concentration-response curve.

One application of the yeast growth assay involves the neoreceptor concept [20] for the P2Y<sub>1</sub> receptors. Because P2 receptors are widespread in most tissues, many side effects could potentially occur during therapeutic intervention. To overcome this problem, the use of receptor engineering, agonist design, and gene therapy has been proposed in what is known as the neoreceptor concept [20]. One of the difficulties in this process is the identification of potential neoreceptors, because site-directed mutagenesis can be laborious. Insight gained from modeling approaches [30] helps to predict potential mutagenesis sites, but this rational approach has met with only mild success. An alternative approach is to use the power of yeast genetics and screening to create libraries of potential neoreceptors and then screen for possible candidates rapidly [31]. This technique was used in the identification of constitutively active mutant receptors and in other applications [16,17]. In this study, 3AM-ATP was studied as a potential neoligand because of its charged nature caused by the amino group. Results showed that 3AM-ATP was only mildly potent in either the yeast or calcium measurements, thus leaving the possibility that the compound could potentially have enhanced affinity for a neoreceptor via an electrostatic interaction.

A concern with the yeast assays is that the incubation period occurred over several days, during which the compound stability was questionable. For example, ATP could be broken down to ADP and further to adenosine. Previous work was performed with yeast systems and purinergic ligands [32,33]. Our data in yeast ( $EC_{50}$ : 2-MeSADP = 130 nM, ADP = 1800 nM) compare well with those of previous work [33] that used a yeast system ( $EC_{50}$ : 2-MeSADP = 300 nM, ADP = 2300 nM), in which a different reporter system was used, allowing for shorter incubation times (24 h). Furthermore, the potencies of these compounds in the yeast system are similar to those from the assay of inositol phosphates (Table 1). The agreement among these data suggests that the longer incubation times in our studies did not significantly alter the results. The nature of the yeast assay is such that the cells multiply numerous times, requiring more agonist over time for continued growth. When measurements were recorded at an earlier time point, the same trends were observed, suggesting that agonist effect was persistent in the medium over time. This constancy in the effect may indicate that the agonist species is largely unchanged over time, although the stability of the nucleotides has not been directly determined.

In general, both the yeast and calcium data were obtained efficiently but should be analyzed with caution, as a clear discrepancy in the potency of some agonists was observed. The yeast system to measure G protein-level events may be a unique measure of these events, because the traditional GTP $\gamma$ S binding assay for G proteins has not been applied successfully to the P2Y<sub>1</sub> receptor. As a complement to classical measurements (radioligand binding, PLC), these assays can provide another measure of functionality rapidly, and taken together the information could lead to the best ways to screen and characterize novel ligands.

In summary, the human P2Y<sub>1</sub> receptor was functionally expressed in yeast, and for a variety of known agonists, the rank order of potencies was similar to that found in other assay systems. The results suggest that the yeast expression system is suitable for screening P2Y<sub>1</sub> receptor ligands, both agonists and antagonists.

### Acknowledgments

We thank Dr. Mark H. Pausch, Dr. Clarice Schmidt, and Dr. Aishe Chen for helpful discussions. We thank Dr. T. Kendall Harden (Univ. North Carolina) for the gift of 1321N1 human astrocytoma cells stably expressing human P2Y<sub>1</sub> receptors. RTN was supported by NSF IGERT funding.

### Abbreviations:

ADP, adenosine 5'-diphosphate  
 ADP-β-S, adenosine 5'-O-(2-thio-diphosphate)  
 3AM-ATP, 3'-amino-3'-deoxy-ATP  
 ATP, adenosine 5'-triphosphate  
 3-AT, 3-amino-1,2,4-triazole  
 FLIPR, fluorescence-imaging plate reader  
 GAPDH, glyceraldehyde-3-phosphate dehydrogenase  
 GPCR, G protein-coupled receptor  
 HT-AMP, 2-hexylthioadenosine 5'-monophosphate  
 IP3, inositol trisphosphate  
 2-MeSADP, 2-methylthioadenosine 5'-diphosphate  
 MRS2179, N<sup>6</sup>-methyl-2'-deoxyadenosine-3',5'-bisphosphate  
 MRS2279, 2-chloro- N<sup>6</sup>-methyl-(N)-methanocarpa-2'-deoxyadenosine-3',5'-bisphosphate  
 PLC, phospholipase C  
 PAPET-ATP, 2-[4-amino(2-phenylethyl)thio]-ATP  
 PBS, phosphate-buffered saline  
 SC, synthetic complete  
 SCURA, SC media lacking uracil  
 SC-URA-HIS, SC media lacking uracil and histidine  
 UDP, uridine 5'-diphosphate  
 UTP, uridine 5'-triphosphate


### References

1. Burnstock G, Fischer B, Hoyle C, Maillard M, Ziganshin AU, Brizzolara AL, von Isakovics A, Boyer JL, Harden TK, Jacobson KA. Structure activity relationships for derivatives of adenosine-5'-triphosphate as agonists at P2 purinoceptors—heterogeneity within P2X and P2Y subtypes. *Drug Dev Res* 1994;31(3):206–19.
2. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. *Pharmacol Rev* 1998;50(3):413–92. [PubMed: 9755289]
3. Jacobson KA, Jarvis MF, Williams M. Purine and pyrimidine (P2) receptors as drug targets. *J Med Chem* 2002;45(19):4057–93. [PubMed: 12213051]
4. Harden TK, Stephens L, Hawkins PT, Downes CP. Turkey erythrocyte membranes as a model for regulation of phospholipase C by guanine nucleotides. *J Biol Chem* 1987;262(19):9057–61. [PubMed: 3036841]
5. Niedernberg A, Tunaru S, Blaukat A, Harris B, Kostenis E. Comparative analysis of functional assays for characterization of agonist ligands at G protein-coupled receptors. *J Biomol Screen* 2003;8(5):500–10. [PubMed: 14567777]
6. Bartfai T, Benovic JL, Bockaert J, Bond RA, Bouvier M, Christopoulos A, Civelli O, Devi LA, George SR, Inui A, Kobilka B, Leurs R, Neubig R, Pin JP, Quirion R, Roques BP, Sakmar TP, Seifert R, Stenkamp RE, Strange PG. The state of GPCR research in 2004. *Nat Rev Drug Discov* 2004;3(7):577–626.
7. Cattaneo M, Lecchi A, Ohno M, Joshi BV, Besada P, Tchilibon S, Lombardi R, Bischoffberger N, Harden TK, Jacobson KA. Antiaggregatory activity in human platelets of potent antagonists of the P2Y<sub>1</sub> receptor. *Biochem Pharmacol* 2004;68:1995–2002. [PubMed: 15476670]


8. Hechler B, Vigne P, Leon C, Breittmayer JP, Gachet C, Frelin C. ATP derivatives are antagonists of the P2Y<sub>1</sub> receptor: similarities to the platelet ADP receptor. *Mol Pharmacol* 1998;53(4):727–33. [PubMed: 9547364]
9. Palmer RK, Boyer JL, Schachter JB, Nicholas RA, Harden TK. Agonist action of adenosine triphosphates at the human P2Y<sub>1</sub> receptor. *Mol Pharmacol* 1998;54(6):1118–23. [PubMed: 9855642]
10. Camaioni E, Boyer JL, Mohanram A, Harden TK, Jacobson KA. Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y<sub>1</sub> receptors. *J Med Chem* 1998;41(2):183–90. [PubMed: 9457242]
11. Leberer E, Thomas DY, Whiteway M. Pheromone signalling and polarized morphogenesis in yeast. *Curr Opin Genet Dev* 1997;7(1):59–66. [PubMed: 9024634]
12. King K, Dohlman HG, Thorner J, Caron MG, Lefkowitz RJ. Control of yeast mating signal transduction by a mammalian beta 2-adrenergic receptor and G<sub>s</sub>alpha subunit. *Science* 1990;250(4977):121–23. [PubMed: 2171146]
13. Price LA, Kajkowski EM, Hadcock JR, Ozenberger BA, Pausch MH. Functional coupling of a mammalian somatostatin receptor to the yeast pheromone response pathway. *Mol Cell Biol* 1995;15(11):6188–95. [PubMed: 7565771]
14. Price LA, Strnad J, Pausch MH, Hadcock JR. Pharmacological characterization of the rat A<sub>2A</sub> adenosine receptor functionally coupled to the yeast pheromone response pathway. *Mol Pharmacol* 1996;50(4):829–37. [PubMed: 8863827]
15. Dowell SJ, Brown AJ. Yeast assays for G protein-coupled receptors. *Recept Channels* 2002;8(56):343–52. [PubMed: 12690961]
16. Beukers MW, van Oppenraaij J, van der Hoorn PP, Blad CC, den Dulk H, Brouwer J, IJzerman AP. Random mutagenesis of the human adenosine A<sub>2B</sub> receptor followed by growth selection in yeast. Identification of constitutively active and gain of function mutations. *Mol Pharmacol* 2004;65(3):702–10. [PubMed: 14978249]
17. Schmidt C, Li B, Bloodworth L, Erlenbach I, Zeng FY, Wess J. Random mutagenesis of the M<sub>3</sub> muscarinic acetylcholine receptor expressed in yeast. Identification of point mutations that “silence” a constitutively active mutant M<sub>3</sub> receptor and greatly impair receptor/G protein coupling. *J Biol Chem* 2003;278(32):30248–60. [PubMed: 12750375]
18. Hoffmann C, Moro S, Nicholas RA, Harden TK, Jacobson KA. The role of amino acids in extracellular loops of the human P2Y<sub>1</sub> receptor in surface expression and activation processes. *J Biol Chem* 1999;274(21):14639–47. [PubMed: 10329657]
19. Gao ZG, Mamedova L, Tchilibon S, Gross AS, Jacobson KA. 2,2'-Pyridylisatogen tosylate antagonizes P2Y<sub>1</sub> receptor signaling without affecting nucleotide binding. *Biochem Pharmacol* 2004;68(2):231–37. [PubMed: 15193995]
20. Jacobson KA, Gao ZG, Chen A, Barak D, Kim SA, Lee K, Link A, Van Rompaey P, Van Calenbergh S, Liang BT. Neoreceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A<sub>3</sub> receptor with selectively enhanced affinity for amine-modified nucleosides. *J Med Chem* 2001;44(24):4125–36. [PubMed: 11708915]
21. Fischer B, Boyer JL, Hoyle CV, Ziganshin AU, Brizzolara AL, Knight GE, Zimmet J, Burnstock G, Harden TK, Jacobson KA. Identification of potent, selective P2Y-purinoceptor agonists: structure activity relationships for 2-thioether derivatives of adenosine-5'-triphosphate. *J Med Chem* 1993;36:3937–46. [PubMed: 8254622]
22. Boyer JL, Siddiqi S, Fischer B, Romero-Avila T, Jacobson KA, Harden TK. Identification of potent P2Y-purinoceptor agonists that are derivatives of adenosine 5'-monophosphate. *Br J Pharmacol* 1996;118(8):1959–64. [PubMed: 8864529]
23. Waldo GL, Corbitt J, Boyer JL, Ravi G, Kim HS, Ji XD, Lacy J, Jacobson KA, Harden TK. Quantitation of the P2Y<sub>1</sub> receptor with a high affinity radiolabeled antagonist. *Mol Pharmacol* 2002;62(5):1249–57. [PubMed: 12391289]
24. Erlenbach I, Kostenis E, Schmidt C, Hamdan FF, Pausch MH, Wess J. Functional expression of M<sub>1</sub>, M<sub>3</sub> and M<sub>5</sub> muscarinic acetylcholine receptors in yeast. *J Neurochem* 2001;77(5):1327–37. [PubMed: 11389184]



25. Jiang Q, Guo D, Lee BX, Van Rhee AM, Kim YC, Nicholas RA, Schachter JB, Harden TK, Jacobson KA. A mutational analysis of residues essential for ligand recognition at the human P2Y<sub>1</sub> receptor. *Mol Pharmacol* 1997;52(3):499–507. [PubMed: 9281613]
26. Sherman F. Getting started with yeast. *Methods Enzymol* 1991;194:3–21. [PubMed: 2005794]
27. Gietz RD, Woods RA. Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method. *Methods Enzymol* 2002;350:87–96. [PubMed: 12073338]
28. Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. *Br J Pharmacol* 1959;14(1):48–58.
29. Brown AJ, Dyos SL, Whiteway MS, White JH, Watson MA, Marzioch M, Clare JJ, Cousens DJ, Paddon C, Plumpton C, Romanos MA, Dowell SJ. Functional coupling of mammalian receptors to the yeast mating pathway using novel yeast/mammalian G protein alpha-subunit chimeras. *Yeast* 2000;16(1):11–22. [PubMed: 10620771]
30. Moro S, Guo D, Camaioni E, Boyer JL, Harden TK, Jacobson KA. Human P2Y<sub>1</sub> receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. *J Med Chem* 1998;41(9):1456–66. [PubMed: 9554879]
31. Montesana PE, Dosil M, Konopka JB. Functional assays for mammalian G-protein-coupled receptors in yeast. *Methods Enzymol* 2002;344:92–111. [PubMed: 11771426]
32. Pausch MH, Lai M, Tseng E, Paulsen J, Bates B, Kwak S. Functional expression of human and mouse P2Y<sub>12</sub> receptors in *Saccharomyces cerevisiae*. *Biochem Biophys Res Commun* 2004;324(1):171–77. [PubMed: 15464998]
33. Gearing KL, Barnes A, Barnett J, Brown A, Cousens D, Dowell S, Green A, Patel K, Thomas P, Volpe F, Marshall F. Complex chimeras to map ligand binding sites of GPCRs. *Protein Eng* 2003;16(5):365–72. [PubMed: 12826728]
34. Moro S, Hoffmann C, Jacobson KA. Role of the extracellular loops of G protein-coupled receptors in ligand recognition: a molecular modeling study of the human P2Y<sub>1</sub> receptor. *Biochemistry* 1999;38(12):3498–507. [PubMed: 10090736]




**Figure 1.**  
**Yeast growth assays in the presence of 2-MeSADP, ADP, ATP.** Representative data exhibiting the concentration-dependent growth (represented as OD<sub>630</sub>) of the engineered yeast strain expressing P2Y<sub>1</sub> receptors in the presence of 2-MeSADP, ADP, and ATP ranging in concentration from 10<sup>-10</sup> to 10<sup>-3</sup> (M). The EC<sub>50</sub> values averaged over at least three experiments are 2-MeSADP (130 nM) > ADP (1800 nM) > ATP (28000 nM). Experiments were performed at least three times with representative data shown. Within each experiment each data point was done in triplicate and averaged.




**Figure 2.**

**Yeast growth assay in the presence of the antagonist MRS2179.** MRS2179 (N<sup>6</sup>-methyl-2-deoxyadenosine-3',5'-bisphosphate) was used to antagonize ADP (adenosine 5'-diphosphate) via a yeast growth assay (represented as OD630). The MRS2179 concentration was fixed at either 0, 10<sup>-6</sup>, 10<sup>-5</sup>, or 10<sup>-4</sup> (M) over an ADP range of 10<sup>-10</sup>–10<sup>-4</sup> M. Increasing amounts of antagonist (10<sup>-6</sup>, 10<sup>-5</sup>, 10<sup>-4</sup> M) cause a right shift in the curves. Each experimental data point was done in triplicate and averaged.



**Figure 3.**  
**Effects of MRS2179 on ADP-induced calcium mobilization in astrocytoma cells.** a) MRS2179 was used to antagonize the effects of the agonist ADP in the calcium mobilization assay. The MRS2179 concentration was fixed at either 0,  $5 \times 10^{-6}$ ,  $10^{-6}$ ,  $10^{-5}$ , or  $5 \times 10^{-4}$  (M) over an ADP range of  $10^{-10}$ – $10^{-5}$  (M). Increasing amounts of antagonist cause a right shift in the curves. Each experimental data point was done in duplicate and averaged. b) A Schild analysis was performed to calculate a  $K_B$  of 164 nM.



**Figure 4.**  
**Effects of MRS2179 on calcium mobilization induced by HT-AMP in astrocytoma cells.**  
a) MRS2179 was used to antagonize the effects of the agonist HT-AMP in the calcium mobilization assay. The MRS2179 concentration was fixed at either 0,  $10^{-6}$ ,  $5 \times 10^{-5}$ ,  $10^{-5}$ , or  $5 \times 10^{-4}$  (M) over an HT-AMP range of  $10^{-10}$ – $10^{-4}$  (M). Increasing amounts of antagonist cause a right shift in the curves. Each experimental data point was done in duplicate and averaged. b) A Schild analysis was performed to calculate a  $K_B$  of 70 nM.



**Table 1**

Potencies of adenine nucleotide derivatives measured in three functional assays of human P2Y<sub>1</sub> receptors and in a receptor binding assay.<sup>a</sup>

	Yeast growth	Functional Potency (EC <sub>50</sub> , nM)		Binding (K <sub>i</sub> , nM)
		PLC (Astrocytoma)	Calcium (astrocytoma)	Astrocytoma
ADP	1800 ± 650	660 <sup>b</sup>	58 ± 17	900 <sup>b</sup>
2-MeSADP	130 ± 43	36 <sup>b</sup>	1.7 ± 0.2	57 <sup>b</sup>
ATP	28,000 ± 18000	2600 <sup>b</sup>	5400 ± 3600	1200 <sup>b</sup>
ADP-β-S	21,000 ± 9800	ND	86 ± 42	710
HT-AMP	24,000 ± 3900	1400 <sup>c</sup>	16 ± 11	1700
PAPET-ATP	17,000 ± 6500	ND	28 ± 13	1100
3AM-ATP	9200 (n=1)	10,000 <sup>d</sup>	3000 ± 1500	ND

<sup>a</sup>Unless noted, the following methods were used, as described in Materials and Methods (n = 3, unless noted): The parameter measured in the engineered yeast cells was growth, indicated by turbidity determinations. The activity designated PLC in 1321N1 astrocytoma cells stably expressing the human P2Y<sub>1</sub> receptor represents the accumulation of tritiated inositol phosphates isolated with ion exchange columns [4,25]. Calcium transients in the same cells were measured with a fluorescent chelating dye method on a FlexStation in 96-well format. K<sub>i</sub> values refer to competition for binding of [<sup>3</sup>H]MRS2279 [23].

<sup>b</sup>Data from Gao et al., 2004 (astrocytoma cells) [19].

<sup>c</sup>Data from Hoffmann et al., 1999 (COS-7 cells) [18].

<sup>d</sup>Data from Moro et al., 1999 (COS-7 cells) [34]. ND = not determined.